In patients with no indication for anticoagulation after TAVR, rivaroxaban increased adverse events vs antiplatelets

ACP Journal Club21 April 2020In patients with no indication for anticoagulation after TAVR, rivaroxaban increased adverse events vs antiplateletsWern Yew Ding, MBChB, Mark Field, DPhil (Oxon), FRCS (C-Th), Gregory Y.H. Lip, MDWern Yew Ding, MBChBUniversity of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, England, UK (W.Y.D., M.F., G.Y.L.)Search for more papers by this author, Mark Field, DPhil (Oxon), FRCS (C-Th)University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, England, UK (W.Y.D., M.F., G.Y.L.)Search for more papers by this author, Gregory Y.H. Lip, MDUniversity of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, England, UK (W.Y.D., M.F., G.Y.L.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/ACPJ202004210-040 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationDangas GD, Tijssen JGP, Wöhrle J, et al. A controlled trial of rivaroxaban after transcatheter aortic-valve replacement. N Engl J Med. 2020;382:120-9. https://pubmed.ncbi.nlm.nih.gov/31733180Clinical Impact RatingsCardiology: Reference1 Siddamsetti S, Balasubramanian S, Yandrapalli S, et al. Meta-analysis comparing dual antiplatelet therapy versus single antiplatelet therapy following transcatheter aortic valve implantation. Am J Cardiol. 2018;122:1401-8. [PMID: 30340696] Google Scholar Author, Article, and Disclosure InformationAffiliations: University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, England, UK (W.Y.D., M.F., G.Y.L.)Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M19-3041.This article was published at Annals.org on 7 April 2020. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 21 April 2020Volume 172, Issue 8Page: JC40KeywordsAntiplatelet therapyAortic valve replacementAspirinAtrial fibrillationHazard ratioHemorrhageMortalityMyocardial infarctionSafetyVitamin K ePublished: 21 April 2020 Issue Published: 21 April 2020 Copyright & PermissionsCopyright © 2020 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...